---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-020102"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T13:14:31.815629+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates

## Summary
- Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.
- Acclaim-1 Phase 2a expansion targets ~33 patients; interim analysis of first 19 expected Q1 2026, top-line in H1 2026.
- Acclaim-3 Phase 2 expansion plans ~50 patients; futility analysis after 25 patients expected Q1 2026.
- Both Acclaim-1 and Acclaim-3 have FDA Fast Track designation; Acclaim-3 also has Orphan Drug Designation.
- Proceeds from Lincoln Park sales to be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001437749-25-020102
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/0001437749-25-020102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925020102/gnpx20250606c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-020102
- JSON: https://secwatch.observer/filing/0001437749-25-020102.json
- Plain text: https://secwatch.observer/filing/0001437749-25-020102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.